Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

A Multiple Dose Study Of PF-04620110 In Type 2 Diabetes Patients

Phase 1

Completed

Conditions: Type 2 Diabetes Patients

Interventions: Drug: PF-04620110
Drug: Placebo

First Posted Date: 2011-02-17

Last Posted Date: 2012-11-06

Lead Sponsor: Pfizer

Target Recruit Count: 48

Registration Number: NCT01298518

Locations: 🇺🇸
Pfizer Investigational Site, Miami Gardens, Florida, United States

Relative Bioavailability Of A Crizotinib Oral Liquid Formulation To Crizotinib Formulated Capsule

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: crizotinib

First Posted Date: 2011-02-17

Last Posted Date: 2012-02-16

Lead Sponsor: Pfizer

Target Recruit Count: 22

Registration Number: NCT01297595

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

A Study to Assess the Antibody Response of Healthy Chinese Children Who Have Been Vaccinated Previously With 4-doses of Prevenar (a Pneumococcal Vaccine) as Babies and Toddlers

Phase 4

Completed

Conditions: Pneumococcal Disease

Interventions: Procedure: Blood draw

First Posted Date: 2011-02-17

Last Posted Date: 2018-12-19

Lead Sponsor: Pfizer

Target Recruit Count: 335

Registration Number: NCT01298544

Locations: 🇨🇳
Longan County CDC, Longan County, Guangxi, China
🇨🇳
Nanyu Town Hospital, Longan County, Guangxi, China
🇨🇳
Dingdang Town Hospital, Longan County, Guangxi, China

and more 7 locations

Sayana-Uniject Volumetric Delivery

Completed

Conditions: Volume Delivery

Interventions: Other: Uniject

First Posted Date: 2011-02-17

Last Posted Date: 2018-12-07

Lead Sponsor: Pfizer

Target Recruit Count: 25

Registration Number: NCT01298479

Locations: 🇧🇪
Pfizer Investigational Site, Bruxelles, Belgium

Study Of Lybrel In Relation To Venous Thromboembolism

Completed

Conditions: Venous Thrombosis
Pulmonary Embolism
Sinus Thrombosis, Intracranial

Interventions: Drug: Oral Contraceptives containing 20 ug of ethinyl estradiol
Drug: 90ug levonorgestrel / 20 ug ethinyl estradiol

First Posted Date: 2011-02-16

Last Posted Date: 2013-07-17

Lead Sponsor: Pfizer

Target Recruit Count: 598682

Registration Number: NCT01297348

Safety And Tolerability Study Of RN564 In Women With Osteopenia And Healthy Men.

Phase 1

Completed

Conditions: Osteopenia
Osteoporosis
Bone Disease

Interventions: Biological: RN564

First Posted Date: 2011-02-10

Last Posted Date: 2012-06-22

Lead Sponsor: Pfizer

Target Recruit Count: 68

Registration Number: NCT01293487

Locations: 🇺🇸
Ambulatory Diagnostic Center, Coral Gables, Florida, United States
🇺🇸
Gable Diagnostics, Coral Gables, Florida, United States
🇺🇸
MRA Clinical Research, South Miami, Florida, United States

and more 4 locations

A Study to Assess the Safety, Tolerability and Pharmacokinetics of NXL104 Alone and in Combination With Ceftazidime Administered as Single and Repeated Intravenous Doses in Healthy Japanese Subjects

Phase 1

Completed

Conditions: Healthy Male and Female Japanese Volunteers

Interventions: Drug: NXL104
Drug: CAZ104
Drug: Placebo

First Posted Date: 2011-02-08

Last Posted Date: 2017-09-01

Lead Sponsor: Pfizer

Target Recruit Count: 15

Registration Number: NCT01291602

Locations: 🇺🇸
Research Site, Baltimore, Maryland, United States

Varenicline Pregnancy Cohort Study

Completed

Conditions: Malformations

Interventions: Drug: varenicline
Behavioral: cigarette smoke from maternal smoking
Other: Non-Exposure

First Posted Date: 2011-02-07

Last Posted Date: 2023-07-24

Lead Sponsor: Pfizer

Target Recruit Count: 885185

Registration Number: NCT01290445

A Single-centre, Randomised, Double-blind, Placebo-controlled, Four Way Crossover Phase I Study to Investigate the Effect on QT/QTc Interval of Ceftazidime NXL104 or Ceftaroline Fosamil NXL104, Compared With Placebo, Using Moxifloxacin (Avelox®) as a Positive Control, in Healthy Male Volunteers

Phase 1

Completed

Conditions: Healthy Male Volunteers

Interventions: Drug: Placebo Infusion
Drug: NXL104
Drug: Moxifloxacin
Drug: Ceftaroline
Drug: Ceftazidime

First Posted Date: 2011-02-07

Last Posted Date: 2017-09-01

Lead Sponsor: Pfizer

Target Recruit Count: 54

Registration Number: NCT01290900

Locations: 🇺🇸
Research Site, Overland Park, Kansas, United States

A Study To Assess The Efficacy And Safety Of PF-04236921 In Subjects With Crohn's Disease Who Failed Anti-TNF Therapy

Phase 2

Completed

Conditions: Crohn's Disease

Interventions: Drug: PF-04236921 SC injection

First Posted Date: 2011-02-02

Last Posted Date: 2016-01-21

Lead Sponsor: Pfizer

Target Recruit Count: 250

Registration Number: NCT01287897

Locations: 🇺🇸
Digestive Disorders Associates, Annapolis, Maryland, United States
🇧🇪
An Spiessens H.-Hartziekenhuis Roeselare-Menen vzw, Roeselare, Belgium
🇨🇿
Hepato-Gastroenterologie HK, s.r.o., Hradec Kralove, Czech Republic

and more 187 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy